{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:17:54Z","timestamp":1791206274138,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":447,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Regeneron and Sanofi"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jacc.2012.03.007","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T06:34:41Z","timestamp":1332916481000},"page":"2344-2353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":453,"title":["Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin\/Kexin Type 9 Serine Protease, SAR236553\/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"James M.","family":"McKenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Kereiakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Hanotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2012.03.007_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.03.007_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib3","first-page":"567","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib4","first-page":"1769","article-title":"ESC\/EAS Guidelines for the management of dsylipidaemias","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2012.03.007_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.03.007_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2009.02.017","article-title":"The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis","volume":"31","author":"Delahoy","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2012.03.007_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.03.007_bib8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.03.007_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","article-title":"Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets (TNT) study","volume":"100","author":"LaRosa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib11","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low?","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2009.02.040","article-title":"Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study)","volume":"104","author":"Wiviott","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.03.007_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education Program (NCEP) Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2012.03.007_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2012.03.007_bib18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.03.007_bib19","doi-asserted-by":"crossref","first-page":"E2023","DOI":"10.1016\/S0735-1097(11)62023-8","article-title":"REGN727\/SAR236553, a fully human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody: effects on safety and lipid and lipoprotein profiles when administered subcutaneously","volume":"57","author":"Swergold","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib20","first-page":"A23251","article-title":"Safety, lipid, and lipoprotein effects of REGN727\/SAR236553, a fully-human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody administered intravenously to healthy volunteers (abstr)","volume":"122","author":"Swergold","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.03.007_bib21","first-page":"A16265","volume":"124","author":"Swergold","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.03.007_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-2712(18)30645-0","article-title":"The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program","volume":"9","author":"Myers","year":"1989","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.jacc.2012.03.007_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00769-002-0537-0","article-title":"The College of American Pathologists laboratory accreditation program","volume":"7","author":"Rabinovitch","year":"2002","journal-title":"Accred Qual Assur"},{"key":"10.1016\/j.jacc.2012.03.007_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-2275(20)41577-9","article-title":"A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol","volume":"19","author":"Warnick","year":"1978","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2012.03.007_bib25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.03.007_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacc.2012.03.007_bib27","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.03.007_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2012.03.007_bib29","doi-asserted-by":"crossref","first-page":"36K","DOI":"10.1016\/j.amjcard.2005.08.006","article-title":"Assessment of reaching goals in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B","volume":"96","author":"Stein","year":"2005","journal-title":"Am J Cardiol"},{"issue":"4A","key":"10.1016\/j.jacc.2012.03.007_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.03.007_bib31","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.03.007_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.clindermatol.2006.07.007","article-title":"Cutaneous vasculitis: diagnosis and management","volume":"24","author":"Carlson","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jacc.2012.03.007_bib33","first-page":"1942","article-title":"Drug associated cutaneous vasculitis in adults in northwestern Spain","volume":"26","author":"Garcia-Porr\u00faa","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacc.2012.03.007_bib34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712008741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712008741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:52:08Z","timestamp":1760014328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109712008741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":34,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0735109712008741"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2012.03.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717949611.793454812","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin\/Kexin Type 9 Serine Protease, SAR236553\/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2012.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}